Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
135,353,273
-
Share change
-
-2,820,113
-
Total reported value
-
$167,810,413
-
Put/Call ratio
-
156%
-
Price per share
-
$1.24
-
Number of holders
-
114
-
Value change
-
-$4,484,424
-
Number of buys
-
45
-
Number of sells
-
48
Institutional Holders of VISTAGEN THERAPEUTICS INC - COM NEW (VTGN) as of Q1 2022
As of 31 Mar 2022,
VISTAGEN THERAPEUTICS INC - COM NEW (VTGN) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
135,353,273 shares.
The largest 10 holders included
NEA Management Company, LLC, VR Adviser, LLC, ORBIMED ADVISORS LLC, ACUTA CAPITAL PARTNERS, LLC, BlackRock Inc., COMMODORE CAPITAL LP, FRANKLIN RESOURCES INC, VANGUARD GROUP INC, SPHERA FUNDS MANAGEMENT LTD., and Nicholas Investment Partners, LP.
This page lists
114
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.